Pro-oncogenic, intra host viral quasispecies in Diffuse large B cell lymphoma patients with occult Hepatitis B Virus infection.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
10 10 2019
Historique:
received: 19 11 2018
accepted: 26 09 2019
entrez: 12 10 2019
pubmed: 12 10 2019
medline: 12 11 2020
Statut: epublish

Résumé

Non Hodgkin lymphoma, predominantly Diffuse Large B-cell Lymphoma (DLBCL) has been reported to have a significant association with Hepatitis B virus (HBV). We investigated the presence of different gene segments of HBV in plasma, B-cells and tumor tissues from DLBCL patients and explored the genetic variability of HBV within and across different compartments in a host using Next Generation Sequencing. Despite all 40 patients being HBV seronegative, 68% showed evidence of occult HBV. Sequencing of these gene segments revealed inter-compartment viral variants in 26% of them, each with at least one non-synonymous mutation. Between compartments, core gene variants revealed Arg94Leu, Glu86Arg and Ser41Thr while X gene variants revealed Phe73Val, Ala44Val, Ser146Ala and Ser147Pro. In tumor compartments per se, several mis-sense mutations were detected, notably the classic T1762A/A1764G mutation in the basal core promoter. In addition, a virus surface antigen mis-sense mutation resulting in M125T was detected in all the samples and could account for surface antigen negativity and occult HBV status. It would be interesting to further explore if a temporal accumulation of viral variants within a favored niche, like patients' lymphocytes, could bestow survival advantage to the virus, and if certain pro-oncogenic HBV variants could drive lymphomagenesis in DLBCL.

Identifiants

pubmed: 31601912
doi: 10.1038/s41598-019-51157-1
pii: 10.1038/s41598-019-51157-1
pmc: PMC6787061
doi:

Substances chimiques

DNA, Viral 0
Hepatitis B Surface Antigens 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

14516

Références

Sci Rep. 2016 Jul 27;6:30374
pubmed: 27461034
Dig Dis Sci. 2015 May;60(5):1315-24
pubmed: 25567052
J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:123-30
pubmed: 21199523
World J Gastroenterol. 2014 Jun 28;20(24):7653-64
pubmed: 24976703
Intern Med J. 2010 Sep;40(9):633-41
pubmed: 19811561
J Clin Microbiol. 2015 Jun;53(6):1831-5
pubmed: 25788548
Gastroenterology. 2004 Jan;126(1):102-10
pubmed: 14699492
World J Hepatol. 2015 Nov 28;7(27):2729-39
pubmed: 26644816
Clin Vaccine Immunol. 2011 Jun;18(6):914-21
pubmed: 21490166
Jundishapur J Microbiol. 2015 Nov 21;8(11):e25726
pubmed: 26862382
Clin Res Hepatol Gastroenterol. 2013 Sep;37(4):373-83
pubmed: 23477988
FEMS Microbiol Lett. 1999 May 15;174(2):247-50
pubmed: 10339815
Lancet Oncol. 2010 Sep;11(9):827-34
pubmed: 20688564
J Med Virol. 2016 Dec;88(12):2206-2210
pubmed: 27219865
Am J Blood Res. 2012;2(1):18-28
pubmed: 22432084
Oncogene. 2007 Apr 2;26(15):2166-76
pubmed: 17401425
J Virol. 2009 Oct;83(19):9983-92
pubmed: 19420079
J Virol. 1989 Nov;63(11):4645-52
pubmed: 2677399
Ann Hematol. 2008 Jun;87(6):475-80
pubmed: 18327583
J Med Virol. 2010 Jul;82(7):1115-25
pubmed: 20513073
Med Oncol. 2010 Jun;27(2):310-8
pubmed: 19350421
Egypt J Immunol. 2006;13(1):105-14
pubmed: 17974155
Pathog Glob Health. 2016 Oct - Dec;110(7-8):287-291
pubmed: 27788631
Hepatology. 2007 Jul;46(1):107-12
pubmed: 17526021
World J Gastroenterol. 2016 Apr 7;22(13):3531-46
pubmed: 27053845
Bioinformatics. 2011 Nov 1;27(21):2987-93
pubmed: 21903627
J Egypt Natl Canc Inst. 2015 Mar;27(1):11-8
pubmed: 25716703
Immunol Rev. 2000 Apr;174:98-111
pubmed: 10807510
World J Gastroenterol. 2007 Jan 7;13(1):74-81
pubmed: 17206756
World J Hepatol. 2015 May 18;7(8):1086-96
pubmed: 26052397
Microbiol Mol Biol Rev. 2012 Jun;76(2):159-216
pubmed: 22688811
J Med Virol. 2014 Jan;86(1):156-61
pubmed: 24132580
Virol J. 2010 Aug 27;7:204
pubmed: 20799931
PLoS One. 2014 Oct 15;9(10):e110012
pubmed: 25333524
Clin Microbiol Rev. 2012 Jan;25(1):142-63
pubmed: 22232374
Br J Cancer. 2014 Feb 18;110(4):1066-73
pubmed: 24346287
J Virol. 2004 Jul;78(14):7575-81
pubmed: 15220432
J Cancer Res Clin Oncol. 2012 Dec;138(12):1993-2001
pubmed: 22767316
J Med Virol. 2017 Oct;89(10):1796-1803
pubmed: 28513915
Hepatology. 2000 Jul;32(1):116-23
pubmed: 10869298
Eur J Cancer Prev. 2012 May;21(3):261-7
pubmed: 22433629

Auteurs

Mahua Sinha (M)

Department of Microbiology, Kidwai Cancer Institute, Bengaluru, India. mahuasinha@gmail.com.

Keerthana Sundar (K)

Department of Microbiology, Kidwai Cancer Institute, Bengaluru, India.

C S Premalata (CS)

Department of Pathology, Kidwai Cancer Institute, Bengaluru, India.

Vikas Asati (V)

Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, India.

Alka Murali (A)

Department of Microbiology, Kidwai Cancer Institute, Bengaluru, India.
Institute of Bioinformatics and Applied Biotechnology (IBAB), Bengaluru, India.

Akhilesh Kumar Bajpai (AK)

Shodhaka Life Sciences Pvt. Ltd., Bengaluru, India.

Sravanthi Davuluri (S)

Shodhaka Life Sciences Pvt. Ltd., Bengaluru, India.

Kshitish K Acharya (KK)

Institute of Bioinformatics and Applied Biotechnology (IBAB), Bengaluru, India.
Shodhaka Life Sciences Pvt. Ltd., Bengaluru, India.

K C Lakshmaiah (KC)

Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, India.

Govind Babu K (G)

Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, India.

Linu A Jacob (LA)

Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, India.

Dharam Nandan (D)

Agrigenome Labs Pvt Ltd, Cochin, India.

Dinesh Velayutham (D)

Agrigenome Labs Pvt Ltd, Cochin, India.

Sibnarayan Datta (S)

Molecular Virology Laboratory, Defence Research Laboratory, Tezpur, Assam, India.

R S Jayshree (RS)

Department of Microbiology, Kidwai Cancer Institute, Bengaluru, India.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH